share_log

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

SEC ·  Jun 12 05:58
Summary by Futu AI
James Bligh, the Interim CFO of Conduit Pharmaceuticals, has acquired 37,272 shares of the company's common stock on June 11, 2024. The transaction, classified under the code 'A' for acquisition, was executed directly by Bligh. Following this transaction, Bligh's total direct holdings in the company amount to 37,272 shares. The acquisition is part of a grant, award, or other form of acquisition, as per the transaction details provided.
James Bligh, the Interim CFO of Conduit Pharmaceuticals, has acquired 37,272 shares of the company's common stock on June 11, 2024. The transaction, classified under the code 'A' for acquisition, was executed directly by Bligh. Following this transaction, Bligh's total direct holdings in the company amount to 37,272 shares. The acquisition is part of a grant, award, or other form of acquisition, as per the transaction details provided.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.